September 07, 2018
Business Wire
CORRECTING and REPLACING CureDuchenne Ventures Commits $500,000 to 4D Molecular Therapeutics to Advance Next-Generation AAV Delivery of Gene Therapy
August 30, 2018
Wired
CRISPR HALTED MUSCULAR DYSTROPHY IN DOGS – ARE HUMANS NEXT?
November 15, 2017
Capricor Therapeutics
Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Investigational Cell Therapy
November 08, 2017
Exonics Therapeutics
Exonics Therapeutics Raises $40 Million in Series A Financing
October 04, 2017
Capricor Therapeutics
Capricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress
October 04, 2017
Catabasis Pharmaceuticals
Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD® Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial in First Half 2018
July 27, 2017
Sarepta Therapeutics
Sarepta Therapeutics Announces its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data in Nature Communications
June 22, 2017
Santhera Pharmaceuticals
Santhera’s Raxone® Receives First Positive EAMS Scientific Opinion from UK’s MHRA in Duchenne Muscular Dystrophy
Hike for Hope is operating under the HIKE FOR HOPE FOUNDATION INC
936 W Francis St., Aspen, CO. 81611
Tel: 970-925-6137,
Tax-exempt 501 (c)(3)
charitable organization.
Tax ID 20-3596738